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Relationship between serotonin transporter gene 
polymorphisms and platelet serotonin transporter sites 
among African-American cocaine-dependent individuals 
and healthy volunteers 
Alterations in the serotonin transporter (5-HTT) have been implicated in a variety of psychiatric 
disorders including cocaine dependence. A polymorphism in the promoter region of the 
serotonin transporter gene (5-HTTLPR) appears to influence the expression of 5-HTT in human 
cell lines. We investigated whether 5-HTTLPR variants were related to differences in measures 
of platelet 5-HTT sites in cocaine-dependent patients and healthy volunteers (controls). 
Polymerase chain reaction-based genotyping of a 44 base pair insertion/deletion polymorphism 
in 5-HTTLPR was performed in 138 cocaine-dependent African-American subjects and 60 
African-American controls. This yielded a short (S) and a long (L) allele. Platelet 5-HTT sites 
were measured using the tritiated paroxetine binding assay. Relationships of 5-HTTLPR 
genotypes with Bmax (density of serotonin transporter) and Kd (affinity constant) were examined. 
Bmax values were significantly lower in cocaine-dependent patients (640+/-233) than controls 
(906+/-225) (P<0.001); however, 5-HTTLPR genotype distributions or allele frequencies did 
not differ between the two groups. There were no significant differences in Bmax between the 
three genotypes among cocaine-dependent patients (LL=690+/-246, LS=620+/-235, SS=587+/-
183; P=0.14) or controls (LL=909+/-233, LS=938+/-279, SS=866+/-143; P=0.65). All three 
genotypes in cocaine-dependent patients showed comparable reductions in Bmax from the 
corresponding genotypes in controls. Demographic variables, severity of substance use or 
depression were unrelated to Bmax or 5-HTTLPR genotypes. Although platelet 5-HTT densities 
are reduced in patients with cocaine dependence compared with healthy volunteers, these 
genotypic variations in the serotonin transporter do not seem to influence levels of platelet 5-
HTT in cocaine-dependent patients or healthy volunteers.  
 
Introduction  
Considerable preclinical evidence indicates that serotonergic (5-HT) mechanisms may mediate 
the central effects of cocaine (McMahon and Cunningham, 2001). Acutely, cocaine is found to 
inhibit 5-HT uptake (Cunningham et al., 1996; Castanon et al., 2000), while repeated 
administration of cocaine has been shown to reduce 5-HT levels in neurons (Heidbreder et al., 
1999). Alterations in 5-HT activity also modulate cocaine withdrawal (Baumann and Rothman, 
1998) and influence cocaine-induced expression of early genes in the brain (Humblot et al., 
1998). Moreover, manipulations of the 5-HT system may influence rates of cocaine self-
administration among animals (Kleven and Koek, 1998). Relatively limited data are available 
regarding 5-HT function in cocaine-dependent individuals, but the findings support animal 
studies. For example, studies have reported impaired hormonal responses to 5-HT agents among 
cocaine-dependent patients compared with controls (Buydens-Branchey et al., 1997; 
Handelsman et al., 1998).  
Among the various components of the 5-HT system, the serotonin transporter (5-HTT) is 
critically important in regulating the reuptake of 5-HT into the presynaptic neuron and the 
platelet, and serves as a target site for certain antidepressants (Graham and Langer, 1992; 
Schloss and Williams, 1998). High affinity binding of the cocaine analogue [125I]RTI-55 to the 
5-HTT sites in human brain has been demonstrated (Staley et al., 1994). Moreover, changes in 
5-HTT have been reported in neuroimaging and post-mortem studies of cocaine-abusing 
individuals (Little et al., 1998; Jacobsen et al., 2000). The human 5-HTT protein is found to be 
encoded by a single gene, and a functional biallelic repeat polymorphism in the 5' promotor 
region of 5-HTT (5-HTTLPR) yielding a short (S) and a long (L) variant of the allele has been 
reported (Lesch et al., 1994; Gelernter et al., 1995). The S variant has been found to exert a 
dominant effect and is associated with reduced transcriptional efficiency resulting in reduced 5-
HTT expression in lymphoblasts (Heils et al., 1996; Lesch et al., 1996). Studies of the 5-
HTTLPR polymorphism in substance abusers have yielded conflicting results. While 5-
HTTLPR variants have been associated with alcoholism in some studies (Sander et al., 1997; 
Schuckit et al., 1999; Lichtermann et al., 2000), other studies of substance abusers have not 
confirmed the association (Berrettini and Persico, 1996; Patkar et al., 2001; Kranzler et al., 
2002).  
Investigations of the influences of 5-HTTLPR genotypes on the expression of the 5-HTT in 
human platelets and neurons have not been consistent. While the short variant has been found to 
be associated with reduced platelet binding (Bmax) (Stoltenberg et al., 2002) and reduced platelet 
uptake (Vmax) (Hanna et al., 1998; Greenberg et al., 1999), other investigators have reported no 
effect of the genotypes on both Vmax (Kaiser et al., 2002) and Bmax (Greenberg et al., 1999; 
Preuss et al., 2000). Similarly, reports of a relationship between the 5-HTTLPR genotype and in 
vivo 5-HTT availability that was observed in a neuroimaging study of healthy subjects (Heinz et 
al., 2000) could not be replicated in a similarly designed study (Willeit et al., 2001).  
Most studies investigating the relationship of 5-HTTLPR genotypes with the expression of 5-
HTT have primarily recruited individuals of European background and investigated alcohol 
dependence. There are relatively limited published data among African-American healthy 
volunteers as well as among cocaine abusers, a major public health problem that particularly 
affects minority populations. In a previous smaller sample we had observed that African-
American cocaine-dependent persons had significantly reduced platelet 5-HTT densities 
compared with controls (Patkar et al., 2003). Since the density of platelet 5-HTT sites may be 
influenced by genetic variations in the 5-HTTLPR, we first compared platelet 5-HTT between 
cocaine-dependent patients and controls, and then investigated whether the platelet 5-HTT 
densities were different among the 5-HTTLPR genotypes in patients with cocaine dependence 
and controls. Finally, we examined each genotype of cocaine and control group with respect to 
platelet 5-HTT measures to determine whether cocaine-associated alterations in 5-HTT occur 
across all 5-HTTLPR genotypes.  
 
Subjects  
The data was collected from September 1997 to February 2002. One hundred and thirty-eight 
subjects were recruited from individuals attending a university-affiliated, outpatient substance 
abuse treatment program in Philadelphia. The study was annually approved by the Institutional 
Review Board of Thomas Jefferson University, Philadelphia. Following a description of the 
study, informed consent was obtained. The Structured Clinical Interview for DSM-IV Axis I 
Disorders (First et al., 1997) was then administered. Subjects also underwent a medical history 
review and physical examination. Exclusion criteria included a diagnosis of schizophrenia, 
major depression, bipolar disorder, or schizoaffective disorder, having a serious medical illness, 
pregnancy, and receiving psychotropic medications. If subjects used more than one substance, 
they were included if their primary drug was cocaine. Urine drug screens were obtained for all 
subjects.  
Nearly 90% of the patients in the program were African-American. The sample was restricted to 
African-American subjects to represent the clinical population and to reduce possible ethnic 
variations in allele frequencies. Only subjects who had a history of substance abuse in one or 
more immediate family members, who reported cocaine use in the previous 30 days on the 
Addiction Severity Index (ASI), and who had onset of regular cocaine use before 25 years of 
age were included. The family history was elicited by items on the family history section of the 
ASI. The sample was restricted to individuals with early onset of regular cocaine use, inability 
to sustain abstinence, and having one or more first-degree affected relatives to define a subset of 
cocaine-dependent patients whose addiction may be more likely to influenced by genetic factors 
(McGue et al., 1992).  
Sixty consenting African-American controls were recruited from those responding to local 
advertisements. Control subjects were screened using the Structured Clinical Interview for 
DSM-IV Axis I disorders, urine drug screens, medical and family history review and physical 
examination. They were excluded if they had a current or past history of substance abuse 
(except tobacco), a major psychiatric disorder (schizophrenia, major depression or bipolar 
disorder), serious medical disorders, a positive urine drug screen, were pregnant or were taking 
psychotropic medications.  
 
Assessments  
Subjects and controls were assessed using the Beck Depression Inventory (BDI) (Beck and 
Steer, 1987), and the ASI (McLellan et al., 1992). The ASI was performed only on cocaine-
dependent subjects. The BDI is a widely-used, self-report questionnaire that assesses depressive 
symptomatology during the previous week and requires about 10 min to complete. The ASI is a 
40-min structured interview that has been extensively used for clinical and research purposes. It 
assesses problem severity in seven domains of functioning: drug use, alcohol use, 
employment/support, medical, legal, family/social and psychiatric. For each domain, a 
composite score that ranges from 0 (minimum) to 1 (maximum) is provided to assess the 
adequacy of functioning in these areas during the previous 30 days.  
 
Genotyping  
Genomic DNA was isolated from anticoagulated venous blood using standard techniques 
(Miller et al., 1988). Genotyping for a 44 base pair insertion/deletion polymorphism in the 5' 
promotor region was performed as described by Heils et al. (1996). Briefly, the 5-HTTLPR 
region was amplified using polymerase chain reaction with oligonucleotide primers (5'-
GGCGTTGCCGCTCTGAATTGC and 5'-GAGGGACTGAGCTGGACAACCCAC) to 
generate a 484 base pair (S) or a 528 base pair (L) fragment. The amplified fragments were 
separated on agarose gels, and bands were visualized by ethidium bromide staining and 
ultraviolet illumination. Genotypes were evaluated by investigators who were blind to the status 
of the subject and any discrepancies were resolved by test replication.  
 
[3H]Paroxetine binding assay  
After a minimum of 2 weeks of abstinence from cocaine, 20 ml venous blood was collected in 
ethylendiamine tetraacetic acid-containing tubes at room temperature and processed within 4 h 
to harvest platelets. The platelet pellets were immediately frozen at -80[degrees]C until they 
were assayed. Women were studied in the initial follicular phase of the menstrual cycle. 
Paroxetine binding was performed using techniques described previously (Ozaki et al., 1994). 
Protein concentrations were determined by the method of Lowry et al. (1951). Specific binding 
of [3H]paroxetine binding (Life Science Products Inc, Boston, MA, USA) was determined at six 
different concentrations in the presence and absence of fluoxetine (Sigma Labs, St Louis, MO, 
USA). The intra-assay and interassay coefficients of variation for Bmax were 3.6% and 9.2%, 
respectively. The scatchard analysis of the platelet [3H]paroxetine binding was performed using 
the LIGAND software program to determine transporter densities (Bmax) and affinity constant 
(Kd). The Bmax was expressed as fentomoles per milligram of protein while the Kd was 
expressed as nanomoles per liter. The laboratory personnel were blind to the clinical data.  
 
Statistical analyses  
The allele frequencies and genotype distributions of the 5-HTTLPR variants were calculated for 
cocaine-dependent patients and controls. Chi-square tests were used to compare allele 
frequencies with those predicted by Hardy-Weinberg equilibrium based on allele frequencies 
reported by Lesch et al. (1996). Bmax and Kd values were compared between cocaine-dependent 
patients and controls, and between different genotypes of cocaine-dependent patients using t 
tests (two-tailed) with corrections for unequal variances where necessary or one-way analysis of 
variance (ANOVA) as appropriate. Correlations between variables were performed using 
Pearson product moment or point biserial correlations as appropriate. All calculations were 
performed using SPSS 11.0 software.  
 
Power considerations  
We tested the hypothesis that there was a functional difference in the 5-HTTLPR variants as 
measured by [3H]paroxetine binding in cocaine-dependent subjects and controls. We initially 
computed the power to detect significant differences in Bmax between subjects and controls 
based on our previous studies of 5-HTT in cocaine-dependent patients and controls (Patkar et 
al., 2003). With two-tailed alpha set at 0.05, the power to detect between-group differences in 
Bmax in the current sample of 139 cocaine-dependent subjects and 60 controls was 0.99 
(adjusted r2=0.19). The next set of analyses involved calculating the power to detect a 
relationship between Bmax and 5-HTTLPR genotypes. Since we could not find published data in 
cocaine-dependent patients, we relied on literature that found a significant relationship of 5-
HTTLPR genotypes with platelet 5-HTT binding in 54 alcoholic persons (Stoltenberg et al., 
2002). In this study the effect size (f) was strong (>0.4) as defined by Cohen (1988). We 
assumed a more conservative effect size (f=0.30) for our study. With two-tailed alpha set at 
0.05, and degrees of freedom at 2, the current study had a power of 0.86 and 0.99 to detect main 
effects of the 5-HTTLPR genotype on 5HTT binding in 60 controls and 138 cocaine-dependent 
patients, respectively. Based on these power considerations, we anticipated our sample size 
would be sufficient to be able to address the research questions of the study.  
 
Results  
 
Sample  
From a total of 212 African-American cocaine-dependent subjects and 108 controls who were 
screened, 138 subjects and 60 controls fulfilled the inclusion criteria and had blood samples 
analyzed for 5-HTT binding and 5-HTTLPR genotypes. The subjects (71% male) and controls 
(61% male) did not differ significantly in gender ([chi]2=2.16, degrees of freedom=1, P=0.23). 
However, subjects (36.11+/-6.12 were significantly older than controls (32.60+/-5.74) (t=3.88, 
degrees of freedom=196, P<0.001). Also, subjects (84%) were significantly more likely to be 
unemployed compared with controls (29%) ([chi]2=39.9, degrees of freedom=1, P<0.001). 
Similarly, significant differences were observed between subjects (74% single) and controls 
(46% single) in marital status ([chi]2=6.18, degrees of freedom=1, P<0.01). Cocaine-dependent 
subjects scored significantly higher on the BDI (11.84+/-7.7) than controls (6.24+/-3.43) 
(t=5.26, degrees of freedom=196, P<0.001). The mean age of first drug use was 20.3+/-4.2 
years. Cocaine-dependent subjects had used cocaine for 15.5+/-7.7 years, the average use was 
5.7+/-1.7 rocks per day. Over 80% used cocaine on a daily basis. The ASI composite scores in 
various domains were as follows: medical (0.07+/-0.17), employment (0.87+/-0.28), drug 
(0.24+/-0.21), alcohol (0.23+/-0.22), legal (0.04+/-0.15), family (0.13+/-0.20) and psychiatric 
(0.17+/-0.21). The admission urine drug screens for 35% of the patients was positive for 
cocaine, indicating that more than one-third patients were actively using cocaine at time of 
admission. Of the 63% of patients who were abstinent, the average length of abstinence prior to 
admission was 14.4 days. A significant proportion of the cocaine-dependent subjects had 
additional current and lifetime substance abuse and dependence diagnoses. About 53% had 
abused or were dependent on alcohol, approximately 82% were nicotine dependent, nearly 31% 
were abusing or dependent on marijuana, and about 15% had opioid abuse or dependence 
during their lifetime or at the present time.  
 
Platelet [3H]paroxetine binding in cocaine-dependent patients and controls  
Cocaine-dependent patients showed significantly lower Bmax (639.71+/-234.32) than controls 
(905+/-225.34) (t=55.12, degrees of freedom=196, P<0.001). However, there was no significant 
difference in Kd values between patients (0.24+/-0.21) and controls (0.26+/-0.17) (t=0.81, 
degrees of freedom=196, P=0.42), and the correlation between Bmax and Kd values was not 
statistically significant (r=0.11, P=0.19). The platelet counts did not differ significantly between 
the patients with cocaine dependence (206+/-30 B/l) and control subjects (230+/-40 B/l). Since 
the patients were significantly younger than the controls, we examined but found no significant 
correlation between age and Bmax (r=0.11, P=0.18). Similarly, no correlation was observed 
between paroxetine binding and demographic characteristics, including gender, employment 
and marital status (all [chi]2<1.8, P>0.05 in each case). Also, there were no significant 
correlations between paroxetine Bmax and BDI scores (r=-0.12, P=0.19). We then analyzed the 
data to determine whether the pattern of cocaine use was related to paroxetine binding. No 
significant correlations were observed between Bmax values on the one hand and quantity 
(r=0.04), frequency (r=-0.09) or duration of cocaine use (r=-0.10), or age of first drug use 
(r=0.07) on the other (P>0.05 in each case). We also examined and found no significant 
difference in Bmax between patients who were actively using cocaine at the time of admission 
(positive urine drug screens) and those who had negative admission urine drug screens 
([chi]2=2.38). Also, no significant correlation was observed between length of abstinence and 
Bmax (r=0.11, P=0.26).  
 
Platelet [3H]paroxetine binding and 5-HTTLPR genotypes in cocaine-dependent patients  
The genotype distributions of the 5-HTTLPR polymorphisms among cocaine-dependent 
individuals are presented in Table 1. The allele frequencies were L=164 (59.4%) and S=112 
(40.6%). The genotype distribution for cocaine-dependent subjects ([chi]2=0.98, degrees of 
freedom=2, P=0.61) did not depart from that predicted from the Hardy-Weinberg equilibrium 
(Lesch et al., 1996). ANOVA analyses revealed no significant differences in Bmax values 
between the LL, LS and SS genotypes [F(2, 136)=2.03, P=0.14] (Table 1). Similarly, Kd values 
were not significantly different among the three genotypes [F(2, 136)=0.81, P=0.44]. We also 
analyzed the data by comparing the Bmax values in LL genotype (690+/-246) with those in a 
combination of L/S and S/S genotype (611+/-224), assuming a dominant effect of the S allele, 
and found no significant differences (t=1.71, degrees of freedom=136, P=0.11). Similarly, Kd 
values did not differ between the LL and LS+SS genotype groups (t=0.46, degrees of 
freedom=136, P=0.48). The distribution of Bmax among the three genotypes in cocaine-
dependent patients is summarized in Figure 1.  
No significant differences were observed in the distribution of sex among the different 5-
HTTLPR genotypes ([chi]2=1.36, degrees of freedom=2, P=0.43). The data was also analyzed 
to determine whether the pattern of cocaine use was related to the transporter polymorphisms. 
No significant associations were found between the 5-HTTLPR genotypes on the one hand and 
admission urine drug screen ([chi]2=1.48, degrees of freedom=2, P=0.43), quantity (F=0.45, 
P=0.62), frequency (F=0.41, P=0.66) or duration of cocaine use (F=0.37, P=0.70), age of first 
drug use (F=0.82, P=0.44) or length of abstinence (F=1.19, P=0.21) on the other.  
A significant proportion of the cocaine-dependent subjects had additional current and lifetime 
substance abuse and dependence diagnoses, reflecting the clinical population in urban treatment 
settings. However, no significant differences were found in 5-HTTLPR genotypes among 
patients with cocaine dependence alone and those with current or lifetime alcohol dependence 
and abuse (all [chi]2<2.02, P>0.05). With respect to other major substances (opioid and 
marijuana) also, no relationship was observed between genotypes and Axis I substance use 
diagnoses (all [chi]2<1.65, P>0.05).  
 
 
 
Table 1 
 
 
Figure 1 
 
 
 
 
 
 
Platelet [3H]paroxetine binding and 5-HTTLPR genotypes in controls  
Table 2 summarizes the genotype distributions of the 5-HTTLPR polymorphisms among 
controls. The allele frequencies were L=68 (56.6%) and S=52 (43.4%). There was no departure 
of the genotype distribution from that predicted from the Hardy-Weinberg equilibrium 
([chi]2=0.43, degrees of freedom=2, P=0.87). Similar to findings among cocaine-dependent 
patients, controls showed no significant differences in Bmax [F(2, 58)=0.43, P=0.65] or Kd [F(2, 
58)=0.45, P=0.64] between the LL, LS and SS genotypes (Table 2). When the LL genotype was 
compared with a combination of the L/S and S/S genotype, no significant differences were 
found in Bmax (LL=934+/-242, LS+SS=922+/-218; t=0.85, degrees of freedom=58, P=0.39) or 
Kd (t=0.62, degrees of freedom=58, P=0.47). The distribution of Bmax among the three 
genotypes in cocaine-dependent patients is summarized in Figure 2. There was no significant 
effect of gender ([chi]2=1.14, P>0.05) on genotype distribution in controls.  
 
Table 2 
 
 
Figure 2 
  
Finally, we compared the Bmax values of each genotype in cocaine-dependent patients with the 
corresponding genotype in controls (e.g. SS cocaine with SS controls). All three genotypes in 
cocaine-dependent patients showed comparable but significant reductions in Bmax from the 
corresponding genotypes in controls (t=4.21-5.28, degrees of freedom=31-96, P<0.01 in each 
case).  
 
Discussion  
The study examined the association of 5-HTTLPR polymorphisms with platelet 5-HTT 
measures in cocaine-dependent individuals and healthy volunteers. Contrary to our 
expectations, 5-HTTLPR polymorphisms did not seem to influence 5-HTT parameters expected 
to correlate with altered expression of the protein resulting from the polymorphism. The 
genotype distribution and allele frequencies in our sample were not significantly different from 
those reported among healthy volunteers (Lesch et al., 1996; Heinz et al., 2000) and alcoholic 
subjects (Heinz et al., 2000; Stoltenberg et al., 2002).  
Our results differ from findings from in vitro experiments (Lesch et al., 1996), platelet studies 
(Stoltenberg et al., 2002), Single Photon Emission Computerized Tomography (SPECT) 
investigations (Heinz et al., 2000) and postmortem studies (Little et al., 1998) indicating that 5-
HTTLPR genotypes may influence the 5-HTT expression in healthy volunteers and substance 
abusers. In contrast to a 40-100% difference in mean densities of 5-HTT between LL 
homozygotes and S-carriers that was observed in some of these studies (Lesch et al., 1996; 
Stoltenberg et al., 2002), we found the corresponding values to differ by about 2% in controls 
and about 11% in cocaine-dependent subjects. There could be several explanations for the 
discrepant findings. Our power calculations were based on a relatively limited sample from the 
literature (n=54) (Stoltenberg et al., 2002) and a type II error remains a possibility, because the 
presumed effect size of the polymorphism may differ across various populations. Differences in 
sample characteristics could be another explanation. Most of the studies have recruited 
individuals of European background while our sample consisted entirely of African-American 
individuals; the 5-HTTLPR alleles have been reported to be distributed differently across ethnic 
groups (Lerman et al., 1998). Another reason could be differences in the 5-HTT binding 
technique. For example, both Lesch's and Stoltenberg's groups used [125I]RTI-55 as a 
radioligand, while we employed [3H]paroxetine for binding purposes. It is also possible that 
modulation of the 5-HTT expression by the 5-HTTLPR polymorphism may not be detectable in 
the presence of other influences on platelet 5-HTT regulation such as second messenger systems 
and post-translational modifications (Greenberg et al., 1999; Zahniser and Doolen, 2001). 
Finally, gene sequences other than those within the 5-HTTLPR may also regulate transcription 
and affect 5-HT uptake (Flattem and Blakely, 2000; Kaiser et al., 2002).  
It is worth noting that several well-designed studies involving reasonably sized samples have 
failed to detect an association between platelet 5-HTT and 5-HTTLPR polymorphic variants 
among healthy volunteers (Greenberg et al., 1999), individuals with obsessive compulsive 
disorder (Hanna et al., 1998), unipolar and bipolar patients (Mellerup et al., 2001), and autistic 
persons (Anderson et al., 2002). Our findings lend additional support to the negative literature. 
The data are also consistent with a neuroimaging study of healthy volunteers that found no 
association between 5-HTT availability and 5-HTTLPR polymorphisms (Willeit et al., 2001) 
and similar results in postmortem brains of schizophrenic patients (Naylor et al., 1998). The 
conflicting data in this area indicate that the pattern of 5-HTTLPR effects may vary in different 
populations and environments (Stoltenberg and Burmeister, 2000).  
All three genotypes in patients with cocaine dependence showed significant reductions in Bmax 
from controls. Reduced platelet 5-HTT has been reported in several psychiatric disorders 
including depression (Nemeroff et al., 1994) and alcoholism (Arranz et al., 1999). The question 
whether the reduction in platelet 5-HTT densities among cocaine-dependent persons represent 
trait or state phemonena remains unsettled. While we did not find an effect of 5-HTTLPR 
genotypes on the platelet 5-HTT, we also failed to find an association between measures of 
cocaine use and 5-HTT. Other studies have found an association of 5-HTTLPR with alcoholism 
(Sander et al., 1997) and with response to alcohol (Schuckit et al., 1999). Given the limited data 
in this area, more research is required to clarify whether 5-HTT alterations in substance abuse 
may be related to genotypic variations.  
Certain limitations of our study deserve comment. First, reflecting the clinical population, 
cocaine-dependent individuals abused a variety of other substances; moreover, a high 
proportion of patients and controls smoked tobacco. The additional substance use may have 
affected platelet 5-HTT binding data. Second, there are potential problems of using volunteers 
recruited from advertisements as controls, such as demographic differences and high rates of 
personal and family histories of various illnesses (Adami et al., 2002). Third, although we 
studied patients after 2 weeks of abstinence, this cannot exclude the effects of chronic cocaine 
use on platelet 5-HTT sites. Fourth, while we excluded current Axis I disorders, Axis II 
psychopathology was not assessed. Finally, it is possible that platelet 5-HTT may not mirror 5-
HTT sites in the brain even though the same gene encodes for the 5-HTT on platelets and 
neurons (Lesch et al., 1993).  
In conclusion, the present study could not detect an association between 5-HTTLPR genotypes 
and densities of platelet 5-HTT among African-American cocaine-dependent individuals and 
healthy volunteers. While platelet 5-HTT densities were reduced in cocaine-dependent persons 
from controls, the reduction was comparable across the three genotypes. Considering the 
evidence implicating the 5-HT system in cocaine dependence, further studies, preferably using 
well-defined populations, are required to clarify the genetic influences on 5-HTT expression.  
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